Wunderlich JR - Search Results

1

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Pass HA, et al. Among authors: wunderlich jr. Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23. Cancer J Sci Am. 1998. PMID: 9815296 Clinical Trial.

2

Targeting of cytotoxic cells with heterocrosslinked antibodies.

Segal DM, Wunderlich JR. Segal DM, et al. Among authors: wunderlich jr. Cancer Invest. 1988;6(1):83-92. doi: 10.3109/07357908809077031. Cancer Invest. 1988. PMID: 3284611 Review. No abstract available.

3

Targeting of cytotoxic cells against tumors with heterocrosslinked, bispecific antibodies.

Segal DM, Qian JH, Garrido MA, Perez P, Winkler DF, Wunderlich JR, Snider DP, Valdayo MJ, Titus JA. Segal DM, et al. Among authors: wunderlich jr. Princess Takamatsu Symp. 1988;19:323-31. Princess Takamatsu Symp. 1988. PMID: 3269363

4

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers-Freezer L, White DE. Rosenberg SA, et al. Among authors: wunderlich jr. J Immunol. 1999 Aug 1;163(3):1690-5. J Immunol. 1999. PMID: 10415076 Free PMC article. Clinical Trial.

5

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Rosenberg SA, et al. Among authors: wunderlich jr. Nat Med. 1998 Mar;4(3):321-7. doi: 10.1038/nm0398-321. Nat Med. 1998. PMID: 9500606 Free PMC article. Clinical Trial.

6

Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer.

Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P. Parker LL, et al. Among authors: wunderlich jr. Hum Gene Ther. 2000 Nov 20;11(17):2377-87. doi: 10.1089/104303400750038480. Hum Gene Ther. 2000. PMID: 11096442

7

T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.

Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA. Dudley ME, et al. Among authors: wunderlich jr. Cancer J. 2000 Mar-Apr;6(2):69-77. Cancer J. 2000. PMID: 11069222

8

Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.

Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA. Kawakami Y, et al. Among authors: wunderlich jr. J Immunother. 2000 Jan;23(1):17-27. doi: 10.1097/00002371-200001000-00004. J Immunother. 2000. PMID: 10687134

9

Targeted cytotoxic cells as a novel form of cancer immunotherapy.

Segal DM, Garrido MA, Perez P, Titus JA, Winkler DA, Ring DB, Kaubisch A, Wunderlich JR. Segal DM, et al. Among authors: wunderlich jr. Mol Immunol. 1988 Nov;25(11):1099-103. doi: 10.1016/0161-5890(88)90144-7. Mol Immunol. 1988. PMID: 3265476 No abstract available.

10

Refocusing the immune system to react with human tumors by targeting human lymphocytes with bispecific antibodies.

Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, Wunderlich JR. Garrido MA, et al. Among authors: wunderlich jr. Dev Biol Stand. 1990;71:33-42. Dev Biol Stand. 1990. PMID: 2144834

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results